Drugs / TAVO412
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06761651 | Dec 2023 → Jan 2026 overdue | cancer | Tavotek Biotherapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05548634 | May 2023 → Dec 2025 overdue | cancer | Tavotek Biotherapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAVO412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06761651 ↗ |
| Route | Intravenous | “IV infusion of TAVO412” NCT05548634 ↗ |